v3.20.1

Deferred income | 12 Months Ended
--- | ---
Dec. 31, 2019
Deferred income |
Deferred income | 24. Deferred income The table below illustrates the deferred income captions in the balance sheet as at December 31, 2019 and 2018.
|  |  | December 31,
|  |  | 2019 |  | 2018 |  | 2017
|  |  | (Euro, in thousands)
Deferred income related to contracts |  |  |  |  |  |  |  |  |  |
Gilead collaboration agreement for filgotinib |  |  | € | 780,261 |  | € | 145,798 |  | € | 213,981
Gilead collaboration agreement for drug discovery platform (1) |  |  |  | 2,220,013 |  |  |  |  |  |
AbbVie collaboration for CF |  |  |  |  |  |  | 3,223 |  |  |
Servier collaboration agreement for osteoarthritis |  |  |  |  |  |  |  |  |  | 5,362
Deferred income related to contracts in our fee-for-service segment |  |  |  | 362 |  |  | 471 |  |  | 248
Other deferred income (grants) |  |  |  | 10 |  |  | 309 |  |  | 301
Total deferred income ( long term & current) |  |  | € | 3,000,646 |  | € | 149,801 |  | € | 219,892
(1) This amount comprises an issuance liability for subsequent warrant B of €16,184 thousand. The movement in the non-current and current deferred income is detailed in the table below.
|  |  | Total |  |  | Gilead collaboration agreement for filgotinib |  |  | Gilead collaboration agreement for GLPG1690 |  |  | Gilead collaboration agreement for drug discovery platform (2) |  |  | AbbVie collaboration agreement for CF |  |  | Servier collaboration agreement for osteoarthritis |  |  | Deferred income related to contracts in our fee-for-service segment |  |  | Other
|  |  | (Euro, in thousands)
On Januari 1, 2017 |  | € | 285,612 |  | € | 285,313 |  |  |  |  |  |  |  |  |  |  |  |  |  | € | 47 |  | € | 252
Upfront/license fees received |  |  | 6,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | € | 6,000 |  |  |  |  |  |
Revenue recognition of upfront/license fees |  |  | (71,971) |  |  | (71,333) |  |  |  |  |  |  |  |  |  |  |  | (638) |  |  |  |  |  |
Other movements |  |  | 250 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 202 |  |  | 48
On December 31, 2017 |  |  | 219,892 |  |  | 213,981 |  | € | — |  | € | — |  | € | — |  |  | 5,362 |  |  | 248 |  |  | 300
Reclassified from equity following adoption of IFRS 15 |  |  | 83,220 |  |  | 43,832 |  |  |  |  |  |  |  |  | 44,749 |  |  | (5,362) |  |  |  |  |  |
Upfront received |  |  | 38,874 |  |  |  |  |  |  |  |  |  |  |  | 38,874 |  |  |  |  |  |  |  |  |
Milestones received |  |  | 20,965 |  |  | 12,417 |  |  |  |  |  |  |  |  | 8,548 |  |  |  |  |  |  |  |  |
Revenue recognition of upfront |  |  | (148,985) |  |  | (96,809) |  |  |  |  |  |  |  |  | (52,176) |  |  |  |  |  |  |  |  |
Revenue recognition of milestones |  |  | (64,394) |  |  | (27,623) |  |  |  |  |  |  |  |  | (36,771) |  |  |  |  |  |  |  |  |
Other movements |  |  | 229 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 222 |  |  | 7
On December 31, 2018 |  |  | 149,801 |  |  | 145,798 |  |  | — |  |  | — |  |  | 3,224 |  |  | — |  |  | 471 |  |  | 308
Upfront received and impact of initial valuation of share subscription |  |  | 3,655,416 |  |  | 641,663 |  |  | 666,967 |  |  | 2,346,787 |  |  |  |  |  |  |  |  |  |  |  |
Milestones received |  |  | 49,727 |  |  | 27,317 |  |  |  |  |  |  |  |  | 22,410 |  |  |  |  |  |  |  |  |
Significant financing component |  |  | 6,900 |  |  | 6,900 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition of upfront |  |  | (1,009,663) |  |  | (260,207) |  |  | (666,967) |  |  | (80,918) |  |  | (1,570) |  |  |  |  |  |  |  |  |
Revenue recognition of milestones |  |  | (51,156) |  |  | (27,092) |  |  |  |  |  |  |  |  | (24,064) |  |  |  |  |  |  |  |  |
Catch-up effect on closing date (1) |  |  | 245,883 |  |  | 245,883 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other movements |  |  | (46,262) |  |  |  |  |  |  |  |  | (45,856) |  |  |  |  |  |  |  |  | (109) |  |  | (297)
On December 31, 2019 |  | € | 3,000,646 |  | € | 780,261 |  | € | — |  | € | 2,220,013 |  | € | — |  | € | — |  | € | 362 |  | € | 10
| (1) |  | Following the contract amendment, the revenue recognized for filgotinib for the year ended December 31, 2019 included a negative catch-up effect resulting from the decrease in the percentage of completion applied to previously received upfront and milestones for that program.
| (2) |  | The upfront received and the outstanding balance at December 31, 2019 comprise the issuance liabilities for the warrants and the upfront payment allocated to the drug discovery platform. Other movements include the derecognition of warrant issuance liabilities through the share premium account.
The outstanding deferred income balance at December 31, 2019 included €780.3 million related to the collaboration agreement with Gilead for filgotinib (€594.7 million classified as long term deferred income), €2,2 20.0 million, including €16.2 million warrant issuance liability related to subsequent warrant B, related to the collaboration agreement with Gilead for the drug discovery platform (€1,991.6 million classified as long term deferred income) and €0.4 million related to our fee-for-service segment. We refer to note 6 for a detail of the allocation of the transaction price received from Gilead. The adoption of IFRS 15 on January 1, 2018, resulted in a timing difference of revenue recognition between IAS 18 and IFRS 15 which negatively impacted the accumulated losses and increased the amount of deferred income (contract liabilities) by an amount of €83.2 million. The outstanding deferred income balance at December 31, 2018 was all short term and included €145.8 million deferred income related to filgotinib, €3.2 million deferred income related to the collaboration agreement with AbbVie for CF, €0.5 million related to our fee-for-service segment, and €0.3 million deferred grant income.

X
- Definition Deferred income [abstract] + References No definition available. + Details
Name: | glpg_DeferredIncomeAbstract
Namespace Prefix: | glpg_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of deferred income. [Refer: Deferred income] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_10_e&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_DisclosureOfDeferredIncomeExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration